Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 134-140

  Mcgann, Patrick T ^a   Howard, Thad A ^a   Flanagan, Jonathan M ^a   Lahti, Jill M ^a   Ware, Russell E ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chromosome breakage; DNA damage; Hydroxycarbamide; Sickle cell anaemia

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ARTICLE; CHROMOSOME BREAKAGE; CHROMOSOME DAMAGE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA REPAIR; DRUG EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; LONG TERM CARE; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIDE EFFECT;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CROSS-SECTIONAL STUDIES; DNA DAMAGE; DNA REPAIR; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYUREA; MIDDLE AGED;

EID: 79958796043     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08698.x     Document Type: Article

References (44)

1. Ariel, I.M. (1970) Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer, 25, 705-714.
2. Brawley, O.W., Cornelius, L.J., Edwards, L.R., Gamble, V.N., Green, B.L., Inturrisi, C., James, A.H., Laraque, D., Mendez, M., Montoya, C.J., Pollock, B.H., Robinson, L., Scholnik, A.P. & Schori, M. (2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Annals of Internal Medicine, 148, 932-938.
3. Brenner, D.J. & Hall, E.J. (2007) Computed tomography - an increasing source of radiation exposure. New England Journal of Medicine, 357, 2277-2284.
4. Cassileth, P.A. & Hyman, G.A. (1967) Treatment of malignant melanoma with hydroxyurea. Cancer Research, 27, 1843-1845.
5. Charache, S., Dover, G.J., Moore, R.D., Eckert, S., Ballas, S.K., Koshy, M., Milner, P.F., Orringer, E.P., Phillips, Jr, G. & Platt, O.S. (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood, 79, 2555-2565.
6. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine, 332, 1317-1322.
7. Chaube, S. & Murphy, M.L. (1966) The effects of hydroxyurea and related compounds on the rat fetus. Cancer Research, 26, 1448-1457.
8. Denning, S.M., Tuck, D.T., Singer, K.H. & Haynes, B.F. (1987) Human thymic epithelial cells function as accessory cells for autologous mature thymocyte activation. Journal of Immunology, 138, 680-686.
9. Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. British Journal of Haematology, 110, 577-583.
10. Flanagan, J.M., Howard, T.A., Mortier, N., Avlasevich, S.L., Smeltzer, M.P., Wu, S., Dertinger, S.D. & Ware, R.E. (2010) Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutation Research, 698, 38-42.
11. Francis, A.A., Blevins, R.D., Carrier, W.L., Smith, D.P. & Regan, J.D. (1979) Inhibition of DNA repair in ultraviolet-irradiated human cells by hydroxyurea. Biochimica et Biophysica Acta, 563, 385-392.
12. Friedrisch, J.R., Pra, D., Maluf, S.W., Bittar, C.M., Mergener, M., Pollo, T., Kayser, M., da Silva, M.A., Henriques, J.A. & da Rocha Silla, L.M. (2008) DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutation Research, 649, 213-220.
13. Gulbis, B., Haberman, D., Dufour, D., Christophe, C., Vermylen, C., Kagambega, F., Corazza, F., Devalck, C., Dresse, M.F., Hunninck, K., Klein, A., Le, P.Q., Loop, M., Maes, P., Philippet, P., Sariban, E., Van Geet, C. & Ferster, A. (2005) Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood, 105, 2685-2690.
14. Gustashaw, K. (1991) Chromosome stains. In: The ACT Cytogenetics Laboratory Manual, 2nd Edn (ed. by M.J. Barch), pp. 244-246. Raven Press Ltd, New York.
15. Hanft, V.N., Fruchtman, S.R., Pickens, C.V., Rosse, W.F., Howard, T.A. & Ware, R.E. (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood, 95, 3589-3593.
16. Hankins, J.S., Ware, R.E., Rogers, Z.R., Wynn, L.W., Lane, P.A., Scott, J.P. & Wang, W.C. (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 106, 2269-2275.
17. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33-45.
18. Heeney, M.M. & Ware, R.E. (2010) Hydroxyurea for children with sickle cell disease. Hematology/oncology Clinics of North America, 24, 199-214.
19. Kennedy, B.J. & Yarbro, J.W. (1966) Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA, 195, 1038-1043.
20. Khayat, A.S., Antunes, L.M., Guimaraes, A.C., Bahia, M.O., Lemos, J.A., Cabral, I.R., Lima, P.D., Amorim, M.I., Cardoso, P.C., Smith, M.A., Santos, R.A. & Burbano, R.R. (2006) Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clinical and Experimental Medicine, 6, 33-37.
21. Kinney, T.R., Helms, R.W., O'Branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 94, 1550-1554.
22. Leavell, U.W. Jr & Yarbro, J.W. (1970) Hydroxyurea. A new treatment for psoriasis. Archives of Dermatology, 102, 144-150.
23. Letvin, N.L., Linch, D.C., Beardsley, G.P., McIntyre, K.W. & Nathan, D.G. (1984) Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. New England Journal of Medicine, 310, 869-873.
24. Levin, V.A., Edwards, M.S., Wara, W.M., Allen, J., Ortega, J. & Vestnys, P. (1984) 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery, 14, 679-681.
25. Lewis, W.H. & Wright, J.A. (1974) Altered ribonucleotide reductase activity in mammalian tissue culture cells resistant to hydroxyurea. Biochemical and Biophysical Research Communications, 60, 926-933.
26. Li, J.C. & Kaminskas, E. (1987) Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Research, 47, 2755-2758.
27. de Lima, P.D., Cardoso, P.C., Khayat, A.S., Bahia Mde, O. & Burbano, R.R. (2003) Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Genetics and Molecular Research, 2, 328-333.
28. Lofvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematology, 41, 375-381.
29. Lori, F., Malykh, A., Cara, A., Sun, D., Weinstein, J.N., Lisziewicz, J. & Gallo, R.C. (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science, 266, 801-805.
30. de Montalembert, M., Brousse, V., Elie, C., Bernaudin, F., Shi, J. & Landais, P. (2006) Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica, 91, 125-128.
31. Murphy, M.L. & Chaube, S. (1964) Preliminary Survey of Hydroxyurea (Nsc-32065) as a Teratogen. Cancer Chemotherapy Reports, 40, 1-7.
32. Nand, S., Stock, W., Godwin, J. & Fisher, S.G. (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. American Journal of Hematology, 52, 42-46.
33. Oppenheim, J.J. & Fishbein, W.N. (1965) Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Research, 25, 980-985.
34. Platt, O.S., Orkin, S.H., Dover, G., Beardsley, G.P., Miller, B. & Nathan, D.G. (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. Journal of Clinical Investigation, 74, 652-656.
35. Rogers, Z., Thompson, B., Ware, R., Wang, W., Iver, R., Miller, S., Minniti, C., Rana, S., Barredo, J., Toledano, S., Zimmerman, S., Casella, J., Files, B., Waclawiw, M., Gerber, A. & Bonds, D. (2005) Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. Blood (ASH Annual Meeting Abstracts), 106, 3184.
36. Sakano, K., Oikawa, S., Hasegawa, K. & Kawanishi, S. (2001) Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Japanese Journal of Cancer Research, 92, 1166-1174.
37. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9years of treatment. JAMA, 289, 1645-1651.
38. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood, 91, 616-622.
39. Wang, W.C., Wynn, L.W., Rogers, Z.R., Scott, J.P., Lane, P.A. & Ware, R.E. (2001) A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 139, 790-796.
40. Ware, R.E. (2010) How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, 115, 5300-5311.
41. Ware, R., He, J., NA, M., Cheng, C., Flanagan, J. & Sparreboom, A. (2008) Distinct phenotypes of hydroxyurea absorption among children with sickle cell anemia. Blood (ASH Annual Meeting Abstracts), 112, 709.
42. Yarbro, J.W. (1992) Mechanism of action of hydroxyurea. Seminars in Oncology, 19, 1-10.
43. Ziegler-Skylakakis, K., Schwarz, L.R. & Andrae, U. (1985) Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutation Research, 152, 225-231.
44. Zimmerman, S.A., Schultz, W.H., Davis, J.S., Pickens, C.V., Mortier, N.A., Howard, T.A. & Ware, R.E. (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 103, 2039-2045.